2024
Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021.
Skajaa N, Laugesen K, Lauffenburger J, Schwamm L, Sørensen H, Patorno E. Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021. Neurology 2024, 102: e209309. PMID: 38648572, PMCID: PMC11226314, DOI: 10.1212/wnl.0000000000209309.Peer-Reviewed Original ResearchConceptsMedication useOral anticoagulant medicationsGlucose-lowering medication useFactors associated with medication useLipid-lowering medication useSevere strokeIschemic stroke hospitalizationsAntihypertensive medication useAnticoagulant medicationOlder patientsCare of patientsSodium-glucose cotransporter-2 inhibitorsGlucagon-like peptide-1 receptor agonistsStroke preventionAnticoagulant medication useLipid-loweringPeptide-1 receptor agonistsGlucose-loweringReduced life expectancyIschemic strokeCotransporter-2 inhibitorsStroke careCohort of patientsStroke hospitalizationsSecondary ischemic stroke prevention
2023
Effects of Remote Patient Monitoring Use on Care Outcomes Among Medicare Patients With Hypertension : An Observational Study.
Tang M, Nakamoto C, Stern A, Zubizarreta J, Marcondes F, Uscher-Pines L, Schwamm L, Mehrotra A. Effects of Remote Patient Monitoring Use on Care Outcomes Among Medicare Patients With Hypertension : An Observational Study. Annals Of Internal Medicine 2023, 176: 1465-1475. PMID: 37931262, DOI: 10.7326/m23-1182.Peer-Reviewed Original ResearchConceptsObservational studyCare outcomesRemote patient monitoringAcute care encountersHypertension medication usePhysician outpatient visitsAcute care useChronic disease managementReceipt of careBlood pressure dataHypertension careUnique medicationsMedication usePrimary outcomeOutpatient visitsResidual confoundingCare useMedication fillsDays' supplyMedicare patientsCare encountersControl practicesHypertensionPatientsImaging use
2021
Linking the Paul Coverdell National Acute Stroke Program to commercial claims to establish a framework for real-world longitudinal stroke research
Patorno E, Schneeweiss S, George M, Tong X, Franklin J, Pawar A, Mogun H, Moura L, Schwamm L. Linking the Paul Coverdell National Acute Stroke Program to commercial claims to establish a framework for real-world longitudinal stroke research. Stroke And Vascular Neurology 2021, 7: 114-123. PMID: 34750282, PMCID: PMC9067267, DOI: 10.1136/svn-2021-001134.Peer-Reviewed Original ResearchConceptsPaul Coverdell National Acute Stroke ProgramAcute Stroke ProgramClaims dataStroke ProgramStroke severityMedication useMedical historyReal-world patientsCare of patientsCommercial claims dataLongitudinal claims dataMedication utilisationStroke hospitalisationsStroke admissionsMost patientsCommercial ClaimsInpatient dataStroke researchDischarge usePatientsHigh quality linkageUnlinked patientsLab valuesStroke
2016
Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale
Xian Y, Hernandez A, Harding T, Fonarow G, Bhatt D, Suter R, Khan Y, Schwamm L, Peterson E. Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. American Heart Journal 2016, 182: 28-35. PMID: 27914497, DOI: 10.1016/j.ahj.2016.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAnticoagulantsAntithrombinsAtrial FibrillationCohort StudiesDabigatranEmergency TreatmentFemaleHumansMaleMedication Therapy ManagementOutcome and Process Assessment, Health CarePyrazolesPyridinesPyridonesQuality ImprovementRegistriesRivaroxabanStrokeThiazolesUnited StatesWarfarinConceptsAcute ischemic strokeAnticoagulation-related intracerebral hemorrhageIntracerebral hemorrhageIschemic strokeStroke patientsOral anticoagulantsAcute ischemic stroke patientsCurrent treatment patternsLongitudinal medication useMulticenter cohort studyAcute stroke patientsIschemic stroke patientsReal-world clinical decisionsChronic anticoagulation therapyPatient-reported outcomesCritical unmet needChronic anticoagulationGuidelines-StrokeStroke prophylaxisAnticoagulation therapyIndex hospitalizationStroke RegistryCohort studyAcute managementMedication use
2012
Death and Rehospitalization after Transient Ischemic Attack or Acute Ischemic Stroke: One-year Outcomes from the Adherence Evaluation of Acute Ischemic Stroke–Longitudinal Registry
Olson D, Cox M, Pan W, Sacco R, Fonarow G, Zorowitz R, LaBresh K, Schwamm L, Williams L, Goldstein L, Bushnell C, Peterson E, Registry A. Death and Rehospitalization after Transient Ischemic Attack or Acute Ischemic Stroke: One-year Outcomes from the Adherence Evaluation of Acute Ischemic Stroke–Longitudinal Registry. Journal Of Stroke And Cerebrovascular Diseases 2012, 22: e181-e188. PMID: 23273788, DOI: 10.1016/j.jstrokecerebrovasdis.2012.11.001.Peer-Reviewed Original ResearchConceptsTransient ischemic attackAcute ischemic strokeIschemic stroke Longitudinal (AVAIL) registryAIS patientsIschemic attackTIA patientsIschemic strokeAdherence evaluationPrimary composite outcomeOne-year outcomesRehospitalization of patientsRate of deathCause deathGuidelines-StrokePostdischarge riskCause mortalityCause rehospitalizationComposite outcomeHospital dischargeMedication useAdjusted ratesRehospitalizationPreventive guidelinesPatientsOne-year
2009
The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics
Bushnell C, Zimmer L, Schwamm L, Goldstein L, Clapp-Channing N, Harding T, Drew L, Zhao X, Peterson E. The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics. American Heart Journal 2009, 157: 428-435.e2. PMID: 19249411, DOI: 10.1016/j.ahj.2008.11.002.Peer-Reviewed Original ResearchConceptsIschemic stroke Longitudinal (AVAIL) registryTransient ischemic attackIschemic attackRecurrent strokePrevention medicationsLongitudinal registryAdherence evaluationSecondary preventive therapyBaseline patient characteristicsModified Rankin scoreSecondary prevention measuresMedication-taking behaviorSystem-level barriersLevel of adherenceFuture strokeCardiovascular eventsRankin scoreVascular eventsAcute hospitalizationHospital dischargePatient characteristicsPreventive therapySecondary outcomesMedication usePrimary outcome